Complement activation by sulfonated poly(ethylene glycol)-acrylate copolymers through alternative pathway

• Published in: Colloids and surfaces, B, Biointerfaces Vol. 50; no. 2; pp. 141 - 146
• Main Authors: Jang, Hong Seok, Ryu, Kyu Eun, Ahn, Woong Shick, Chun, Heung Jae, Dal Park, Hyung, Park, Ki Dong, Kim, Young Ha
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2006
• Subjects: Acrylate; Acrylates - chemistry; Acrylates - pharmacology; Alternative pathway; Biocompatible Materials - chemistry; Biocompatible Materials - pharmacology; Biomaterials; Coated Materials, Biocompatible; Complement C5a - metabolism; Complement Membrane Attack Complex - metabolism; Complement Pathway, Alternative - drug effects; Copolymerization; Humans; In Vitro Techniques; Materials Testing; Molecular Structure; Poly(ethylene glycol); Polyethylene Glycols - chemistry; Polyethylene Glycols - pharmacology; Sulfonation complement activation; Sulfonation complement activation; Copolymerization; Alternative pathway; Acrylate; Poly(ethylene glycol); Biomaterials
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2006.03.024

Previously, novel poly(ethylene glycol) (PEG) and sulfonated PEG acrylate (PEG-SO 3A/OA) copolymers were prepared as coating and/or blending materials for biomedical applications. Surfaces modified with copolymers exhibited increased anti-coagulation properties and decreased plasma adsorption level due to increased hydrophilic properties and reorientation characteristics of PEG/PEG-SO 3A chains in water phase. As continuation study, anti-complement effects of PEG-SO 3/OA copolymers were investigated in vitro, and compared with those of low-density polyethylene (LDPE) and PEG/OA. C3 activation by PEG-SO 3/OA samples was lower than that by PEG/OA samples, which was attributed to decreased surface nucleophile level of samples. PEG-SO 3/OA samples increased inhibition of Bb production, resulting in decreased C5 activation. Owing to reduced activations of C3 and C5, PEG-SO 3/OA samples markedly decreased SC5b-9 levels in plasma.